Metsera (MTSR) Soars to All-Time High on $7.3-Billion Merger With Pfizer

We recently published 10 Stocks Stealing Wall Street’s Spotlight. Metsera Inc. (NASDAQ:MTSR) is one of the top performers on Monday.

Shares of Metsera Inc. (NASDAQ:MTSR) jumped to a new all-time high on Monday, as investors gobbled up shares following news that it was set to be acquired by Pfizer Inc. (NYSE: PFE) for a potential transaction value of more than $7 billion.

During the session, Metsera Inc. (NASDAQ:MTSR) soared to its highest price of $54.46 before trimming gains to close the day just up by 60.80 percent at $53.58 apiece.

In a statement, the company said it entered into a definitive agreement with Pfizer for the acquisition of all of its outstanding shares at a price of $47.50 apiece.

Additionally, the agreement includes a non-transferable contingent value right (CVR) entitling Metsera Inc. (NASDAQ:MTSR) shareholders to potential additional payments of up to $22.50 per share if it achieves three specific clinical milestones: $5 per share following the Phase 3 clinical trial start of Metsera’s MET-097i+MET-233i combination; $7 per share following Food and Drug Administration (FDA) approval of Metsera’s monthly MET-097i monotherapy; and $10.50 per share following FDA approval of Metsera’s monthly MET-097i+MET-233i combination, if achieved.

The transaction is expected to close in the fourth quarter of 2025.

While we acknowledge the potential of MTSR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.